HIGHLIGHTS
- who: Vivian Changying Jiang from the Department of Lymphoma and Myeloma, the University of Texas MD Anderson Cancer Center, Houston, TX, USA have published the research work: TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma, in the Journal: (JOURNAL)
- what: The authors demonstrate that after BA relapse the proportion of T cells especially cytotoxic T cells (CTLs) decreased among non-tumor cells while the proportion of myeloid cells correspondingly increased. The authors applied unbiased approaches to investigate the potential resistance factors for BA in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.